Stay updated with breaking news from Aematologic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
IMV Inc. , a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced changes to its board... | March 27, 2023
LONDON, Nov. 10, 2022 /PRNewswire/ -- According to the latest market research, The Global Hematologic Malignancies Treatment Market is valued at US$ 51.97 Billion in 2021, and it is expected
IGM Biosciences Announces Third Quarter 2022 Financial Results and Provides Corporate Update - Data from T cell Engager Portfolio for Hematologic Malignancies, Including First... | November 3, 2022
IMV Inc. , a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that members of... | September 1, 2022
Geron Corporation , a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D.,... | August 3, 2022